Yulia Slavina

Definium Therapeutics reports breakthrough with Emerge trial for LSD-based depression therapy

Definium Therapeutics reports breakthrough with Emerge trial for LSD-based depression therapy
Definium LSD depression trial advances

Definium Therapeutics announced today that its Emerge study, the first Phase 3 clinical trial for its pharmaceutical LSD in major depressive disorder (MDD), delivered positive topline results.

The company described the outcome as a major advance toward introducing novel psychiatric treatments, signaling increased momentum for psychedelic-based approaches in mental health care.

Earlier this year, Definium Therapeutics joined peers at ASCP in Miami Beach to present AI-powered advances for psychiatric drug development. The company has also investigated how neuroplasticity and psychedelics may disrupt negative mental cycles. These efforts reflect the firm's continued focus on innovative approaches in mental health.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.